Pain comes in many forms, and Abbott aims to treat as many as it can with its devices. The company received a new approval from the FDA for its low-dose spinal cord stimulator implant, covering peripheral neuropathy caused by diabetes.
Abbott estimates that about half of the 34 million people in the U.S. with Type 1 or Type 2 diabetes will develop the complication, typically caused by nerve damage that brings pain and numbness in the legs, feet and hands.
While the condition doesn’t have a direct treatment, the company said it hopes its Proclaim XR hardware can offer patients an option for managing symptoms outside of oral painkiller medications.
Read more at: https://www.fiercebiotech.com/medtech/abbotts-spinal-cord-stimulator-nets-fda-green-light-diabetes-pain
